Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins

A method of inhibiting Aß1-42 aggregation, Tau aggregation and/or alpha-synuclein aggregation comprising:

• administering to a subject an effective amount of a compound having the formula (I):
• A-L1-B (I)
• or a stereoisomer, racemic mixture, or pharmaceutically acceptable salts thereof;
• wherein A is:
• L1 is:
• B is:
• wherein
• R2 and R3 are each independently selected from the group consisting of hydrogen, halogen, —CN, —CF3, —CONR30R31, —N(R30)—C(O)—R31, a —O—C1-C6 alkyl, and C5-C10 heterocycloalkyl, or wherein R2 and R3 taken together form a 5- or 6-membered ring containing carbon atoms and optionally one or two heteroatoms selected from O, S, or N;
• R1 is hydrogen or halogen;
• Ra is hydrogen or C1-C6 alkyl;
• for each occurrence, Rb is independently selected from the group consisting of:
• hydrogen, halogen, CN, CONR30R31, or C1-C6 alkyl;
• for each occurrence, R30, R31, and R20 are each independently selected from the group consisting of hydrogen, or C1-C6 alkyl;
• Y is CH or N;
• and
• z is 1 or 2, thereby inhibiting Aß1-42 aggregation, Tau aggregation and/or alpha-synuclein aggregation.